The anti-obesity pill has shown no serious side effects

According to phase II clinical trials the results in terms of weight loss of theamicretin – new drug under study – they are even better than those guaranteed by some semglutide-based drugs studied for diabetes and also used off-label for the treatment of obesity. Moreover, the new medicine under development, which has been known about for months but on which further concrete results are now arriving, follows the same principle: that is, it is a medicine, in pill form, which mimics the hormone GLP-1suppressing people’s appetite. And it also mimics theamylina polypeptide protein secreted by the beta cells of the pancreas together with insulin: it also promotes the feeling of satiety slowing gastric emptying

Last Wednesday, drugmaker Novo Nordisk announced that its long-awaited experimental weight-loss pill, amicretin, had been shown to be safe And tolerable for patients in an early-stage trial, with mild to moderate side effectsThe pharmaceutical company, which presented the complete data from the phase I study at the meeting of the European Association for the Study of Diabetes in Madrid, had already declared in March that during the trial of the pill version of amicretin it had detected weight loss in the participants up to 13.1% after 12 weeks. To give you an idea, double the 6% of Ozempic and Wegowy, which rises to 15% only after 68 weeks and which must be injected.

“What we see in the study period is a 13.1% weight loss with a side effect profile comparable to what we normally see with incretin-based therapy, so mainly gastrointestinal side effects,” he explained. Martin Holst Langeresponsible for the development of Novo, in an interview before the presentation. One serious, but not fatal, adverse event was reported during the trial involving 60 participants. There were no reports of serious side effects for patients taking amicretin, while there were a total of 242 reports of effects of the type, as mentioned, mild and moderate.

During the study, overweight or obese patients without diabetes received increasing doses of amicretinstarting at 3 milligrams and up to a final dose of two 50 mg pills. Patients who took 50 mg of amicretin at the end of the 12-week trial had an average 10.4% lower body weight, while those who took the maximum dose of two 50 mg tablets lost 13.1% of their initial weight. This compared to an average weight loss of 1.1% among those who took a placebo. So the trial is ongoing and may jump straight into Phase III after analyzing data on an injectable version of the same drug. “A single molecule that targets both amylin and GLP-1 biology in a tablet form may offer a more convenient approach to achieving better outcomes for overweight or obese individuals,” the researchers wrote.